Anti-Gb3 Monoclonal Antibody Inhibits Angiogenesis and Tumor Development

Ariane Desselle; Tanguy Chaumette; Marie-Hélène Gaugler; Denis Cochonneau; Julien Fleurence; Nolwenn Dubois; Philippe Hulin; Jacques Aubry; Stéphane Birklé; François Paris

doi:10.1371/journal.pone.0045423

Loading metrics

Open Access

Peer-reviewed

Research Article

Anti-Gb3 Monoclonal Antibody Inhibits Angiogenesis and Tumor Development

Ariane Desselle ,

Contributed equally to this work with: Ariane Desselle, Tanguy Chaumette

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France
⨯
Tanguy Chaumette ,

Contributed equally to this work with: Ariane Desselle, Tanguy Chaumette

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France
⨯
Marie-Hélène Gaugler,

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, France
⨯
Denis Cochonneau,

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France
⨯
Julien Fleurence,

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France
⨯
Nolwenn Dubois,

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
⨯
Philippe Hulin,

Affiliation Inserm, SFR Santé UMS 016, Nantes, France
⨯
Jacques Aubry,

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France
⨯
Stéphane Birklé ,

¶These authors also contributed equally to this work.

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France
⨯
François Paris

* E-mail: francois.paris@inserm.fr

¶These authors also contributed equally to this work.

Affiliations Inserm, UMR892, Nantes, France, Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, CNRS, UMR 6299, Nantes, France, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
⨯

Anti-Gb3 Monoclonal Antibody Inhibits Angiogenesis and Tumor Development

Ariane Desselle,
Tanguy Chaumette,
Marie-Hélène Gaugler,
Denis Cochonneau,
Julien Fleurence,
Nolwenn Dubois,
Philippe Hulin,
Jacques Aubry,
Stéphane Birklé,
François Paris

Published: November 26, 2012
https://doi.org/10.1371/journal.pone.0045423

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Endothelial cells
Is the Subject Area "Endothelial cells" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Angiogenesis
Is the Subject Area "Angiogenesis" applicable to this article?

Thanks for your feedback.
Cancer immunotherapy
Is the Subject Area "Cancer immunotherapy" applicable to this article?

Thanks for your feedback.
Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
Antibody therapy
Is the Subject Area "Antibody therapy" applicable to this article?

Thanks for your feedback.